{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:56:51Z","timestamp":1791071811205,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1590,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Cytheris S.A."},{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"crossref","award":["2011-052"],"award-info":[{"award-number":["2011-052"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"crossref","award":["FUI AAP-10 DIVRESCUE"],"award-info":[{"award-number":["FUI AAP-10 DIVRESCUE"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"crossref","award":["OSEO F1105032Z"],"award-info":[{"award-number":["OSEO F1105032Z"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"crossref"}]},{"name":"R\u00e9gion Rh\u00f4ne-Alpes","award":["No 1101030301"],"award-info":[{"award-number":["No 1101030301"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1093\/annonc\/mdv173","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T04:06:21Z","timestamp":1428465981000},"page":"1353-1362","source":"Crossref","is-referenced-by-count":69,"title":["ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients"],"prefix":"10.1016","volume":"26","author":[{"given":"O.","family":"Tr\u00e9dan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"M\u00e9n\u00e9trier-Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cropet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Verron\u00e8se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rebattu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.E.","family":"Heudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Croughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Cadore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Clapisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bardin-dit-Courageot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"N'Kodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gilles-Afchain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Morre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv173_bb0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","article-title":"Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia","volume":"14","author":"Blay","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv173_bb0015","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00280-011-1610-3","article-title":"Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy","volume":"68","author":"Ceze","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdv173_bb0020","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-08-2360","article-title":"Regulatory T cells recruited through CCL22\/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome","volume":"69","author":"Gobert","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv173_bb0025","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.juro.2012.09.166","article-title":"Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma","volume":"189","author":"Saroha","year":"2013","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdv173_bb0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V92.2.405","article-title":"A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy","volume":"92","author":"Blay","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv173_bb0035","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/cncr.20688","article-title":"CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer","volume":"101","author":"Borg","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdv173_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjc.6600724","article-title":"Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy","volume":"88","author":"Ray-Coquard","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv173_bb0045","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/onci.19545","article-title":"Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients","volume":"1","author":"Manuel","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdv173_bb0050","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ejca.2012.11.003","article-title":"CD4 lymphopenia to identify end-of-life metastatic cancer patients","volume":"49","author":"Peron","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv173_bb0055","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1054\/bjoc.2001.2011","article-title":"Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas","volume":"85","author":"Ray-Coquard","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv173_bb0060","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.ejca.2012.11.028","article-title":"Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome","volume":"49","author":"Tredan","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv173_bb0065","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.V97.10.2983","article-title":"A potential role for interleukin-7 in T-cell homeostasis","volume":"97","author":"Fry","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv173_bb0070","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2002-07-2297","article-title":"IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates","volume":"101","author":"Fry","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv173_bb0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2007.01.002","article-title":"Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy","volume":"123","author":"Li","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1093\/annonc\/mdv173_bb0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-012-0210-4","article-title":"Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival","volume":"7","author":"Morre","year":"2012","journal-title":"Target Oncol"},{"key":"10.1093\/annonc\/mdv173_bb0085","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1172\/JCI0214685","article-title":"IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis","volume":"109","author":"Huang","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdv173_bb0090","doi-asserted-by":"crossref","first-page":"e85789","DOI":"10.1371\/journal.pone.0085789","article-title":"Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice","volume":"9","author":"Gou","year":"2014","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdv173_bb0095","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1089\/104303403322495025","article-title":"Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma","volume":"14","author":"Sharma","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1093\/annonc\/mdv173_bb0100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood-2008-11-191288","article-title":"Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques","volume":"114","author":"Beq","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv173_bb0105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.cji.0000210386.55951.c2","article-title":"IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells","volume":"29","author":"Rosenberg","year":"2006","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdv173_bb0110","first-page":"997","article-title":"Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment","volume":"119","author":"Levy","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdv173_bb0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/cid\/cis383","article-title":"Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I\/IIa randomized, placebo-controlled, multicenter study","volume":"55","author":"Levy","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1093\/annonc\/mdv173_bb0120","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20071681","article-title":"Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets","volume":"205","author":"Sportes","year":"2008","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv173_bb0125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1078-0432.CCR-09-1303","article-title":"Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy","volume":"16","author":"Sportes","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv173_bb0130","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1200\/JCO.2002.03.003","article-title":"Factorial design considerations","volume":"20","author":"Green","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv173_bb0135","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2012-06-437236","article-title":"Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation","volume":"120","author":"Perales","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv173_bb0140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nri2970","article-title":"Harnessing the biology of IL-7 for therapeutic application","volume":"11","author":"Mackall","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1093\/annonc\/mdv173_bb0145","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1084\/jem.173.4.923","article-title":"Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes","volume":"173","author":"Alderson","year":"1991","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv173_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11523-012-0208-y","article-title":"Targeting regulatory T cells","volume":"7","author":"Menetrier-Caux","year":"2012","journal-title":"Target Oncol"},{"key":"10.1093\/annonc\/mdv173_bb0155","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/0008-5472.CAN-12-2409","article-title":"ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells","volume":"72","author":"Faget","year":"2012","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv173_bb0160","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","article-title":"Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression","volume":"72","author":"Sisirak","year":"2012","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv173_bb0165","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.4049\/jimmunol.1203547","article-title":"IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39\/ATP axis","volume":"191","author":"Younas","year":"2013","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdv173_bb0170","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/eji.201040531","article-title":"Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells","volume":"40","author":"Simonetta","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1093\/annonc\/mdv173_bb0175","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv173_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"10.1093\/annonc\/mdv173_bb0185","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00262-014-1605-0","article-title":"Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome","volume":"63","author":"Foureau","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/mdv173_bb0190","doi-asserted-by":"crossref","first-page":"e1003630","DOI":"10.1371\/journal.pcbi.1003630","article-title":"Quantifying and predicting the effect of exogenous interleukin-7 on CD4+ T cells in HIV-1 infection","volume":"10","author":"Thiebaut","year":"2014","journal-title":"PLoS Comput Biol"},{"key":"10.1093\/annonc\/mdv173_bb0195","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv173_bb0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/CJI.0b013e31821dcb50","article-title":"Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome","volume":"34","author":"Samlowski","year":"2011","journal-title":"J Immunother"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/7\/1353\/16702763\/mdv173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:53:51Z","timestamp":1624521231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419344989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0923753419344989"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv173","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}